6L9O
 
 | |
5Z9S
 | |
8IVF
 | | FABP7 complexed with 25-HC | | 分子名称: | 25-HYDROXYCHOLESTEROL, Fatty acid-binding protein, brain | | 著者 | Wei, P.C, Zhao, K, Yin, L. | | 登録日 | 2023-03-27 | | 公開日 | 2024-02-28 | | 最終更新日 | 2024-03-13 | | 実験手法 | X-RAY DIFFRACTION (2.6 Å) | | 主引用文献 | Fatty acid-binding proteins 3, 7, and 8 bind cholesterol and facilitate its egress from lysosomes.
J.Cell Biol., 223, 2024
|
|
8IVL
 | | FABP7 complexed with Cholesterol | | 分子名称: | CHOLESTEROL, Fatty acid-binding protein, brain | | 著者 | Wei, P.C, Zhao, K, Yin, L. | | 登録日 | 2023-03-28 | | 公開日 | 2024-02-28 | | 最終更新日 | 2024-03-13 | | 実験手法 | X-RAY DIFFRACTION (2.7 Å) | | 主引用文献 | Fatty acid-binding proteins 3, 7, and 8 bind cholesterol and facilitate its egress from lysosomes.
J.Cell Biol., 223, 2024
|
|
5YLF
 | | MCR-1 complex with D-glucose | | 分子名称: | Probable phosphatidylethanolamine transferase Mcr-1, ZINC ION, beta-D-glucopyranose | | 著者 | Wei, P.C, Song, G.J, Shi, M.Y, Zhou, Y.F, Liu, Y, Lei, J, Chen, P, Yin, L. | | 登録日 | 2017-10-17 | | 公開日 | 2017-11-08 | | 最終更新日 | 2023-11-22 | | 実験手法 | X-RAY DIFFRACTION (1.5 Å) | | 主引用文献 | Substrate analog interaction with MCR-1 offers insight into the rising threat of the plasmid-mediated transferable colistin resistance.
FASEB J., 32, 2018
|
|
5YLC
 | | Crystal Structure of MCR-1 Catalytic Domain | | 分子名称: | Probable phosphatidylethanolamine transferase Mcr-1, ZINC ION | | 著者 | Wei, P.C, Song, G.J, Shi, M.Y, Zhou, Y.F, Liu, Y, Lei, J, Chen, P, Yin, L. | | 登録日 | 2017-10-17 | | 公開日 | 2017-11-08 | | 最終更新日 | 2023-11-22 | | 実験手法 | X-RAY DIFFRACTION (1.5 Å) | | 主引用文献 | Substrate analog interaction with MCR-1 offers insight into the rising threat of the plasmid-mediated transferable colistin resistance.
FASEB J., 32, 2018
|
|
5YLE
 | | MCR-1 complex with ethanolamine (ETA) | | 分子名称: | ETHANOLAMINE, Probable phosphatidylethanolamine transferase Mcr-1, ZINC ION | | 著者 | Wei, P.C, Song, G.J, Shi, M.Y, Zhou, Y.F, Liu, Y, Lei, J, Chen, P, Yin, L. | | 登録日 | 2017-10-17 | | 公開日 | 2017-11-08 | | 最終更新日 | 2023-11-22 | | 実験手法 | X-RAY DIFFRACTION (1.85 Å) | | 主引用文献 | Substrate analog interaction with MCR-1 offers insight into the rising threat of the plasmid-mediated transferable colistin resistance.
FASEB J., 32, 2018
|
|
5XS3
 | | Crystal structure of HLA Class I antigen | | 分子名称: | Heavy Chain, Light Chain, P | | 著者 | Wei, P.C, Yang, Y, Liu, Z.X, Luo, Z.Q, Tu, W.Y, Han, J.Y, Deng, Y.H, Yin, L. | | 登録日 | 2017-06-12 | | 公開日 | 2017-09-13 | | 最終更新日 | 2023-11-22 | | 実験手法 | X-RAY DIFFRACTION (2.5 Å) | | 主引用文献 | Characterization of Autoantigen Presentation by HLA-C*06:02 in Psoriasis
J. Invest. Dermatol., 137, 2017
|
|
6L9K
 | | H2-Ld a1a2 complexed with A5 peptide | | 分子名称: | H2-Ld a1a2, SER-PRO-SER-TYR-ALA-TYR-HIS-GLN-PHE | | 著者 | Wei, P.C, Yin, L. | | 登録日 | 2019-11-10 | | 公開日 | 2020-11-18 | | 最終更新日 | 2023-11-22 | | 実験手法 | X-RAY DIFFRACTION (1.8 Å) | | 主引用文献 | Structures suggest an approach for converting weak self-peptide tumor antigens into superagonists for CD8 T cells in cancer.
Proc.Natl.Acad.Sci.USA, 118, 2021
|
|
6L9N
 | | H2-Ld complexed with A5 peptide | | 分子名称: | MHC, SER-PRO-SER-TYR-ALA-TYR-HIS-GLN-PHE, b2m | | 著者 | Wei, P.C, Yin, L. | | 登録日 | 2019-11-10 | | 公開日 | 2020-11-18 | | 最終更新日 | 2023-11-22 | | 実験手法 | X-RAY DIFFRACTION (2.6 Å) | | 主引用文献 | Structures suggest an approach for converting weak self-peptide tumor antigens into superagonists for CD8 T cells in cancer.
Proc.Natl.Acad.Sci.USA, 118, 2021
|
|
6L9L
 | | 1D4 TCR recognition of H2-Ld a1a2 A5 Peptide Complexes | | 分子名称: | H2-Ld a1a2, SER-PRO-SER-TYR-ALA-TYR-HIS-GLN-PHE, T Cell Receptor | | 著者 | Wei, P.C, Yin, L. | | 登録日 | 2019-11-10 | | 公開日 | 2020-11-18 | | 最終更新日 | 2023-11-22 | | 実験手法 | X-RAY DIFFRACTION (2.399 Å) | | 主引用文献 | Structures suggest an approach for converting weak self-peptide tumor antigens into superagonists for CD8 T cells in cancer.
Proc.Natl.Acad.Sci.USA, 118, 2021
|
|
6L9M
 | | H2-Ld complexed with AH1 peptide | | 分子名称: | H2-Ld, SER-PRO-SER-TYR-VAL-TYR-HIS-GLN-PHE, b2m | | 著者 | Wei, P.C, Yin, L. | | 登録日 | 2019-11-10 | | 公開日 | 2020-11-18 | | 最終更新日 | 2023-11-22 | | 実験手法 | X-RAY DIFFRACTION (2.6 Å) | | 主引用文献 | Structures suggest an approach for converting weak self-peptide tumor antigens into superagonists for CD8 T cells in cancer.
Proc.Natl.Acad.Sci.USA, 118, 2021
|
|
6JQ3
 | | Crystal Structure of H2-Kb in complex with a DPAGT1 mutant peptide | | 分子名称: | Beta-2-microglobulin, DPAGT1 mutant antigen SIIVFNLL, H-2 class I histocompatibility antigen, ... | | 著者 | Bai, P, Zhou, Q, Wei, P, Yin, L. | | 登録日 | 2019-03-28 | | 公開日 | 2020-05-06 | | 最終更新日 | 2021-02-17 | | 実験手法 | X-RAY DIFFRACTION (2.5 Å) | | 主引用文献 | Immune-based mutation classification enables neoantigen prioritization and immune feature discovery in cancer immunotherapy.
Oncoimmunology, 10, 2021
|
|
6JTN
 | | Crystal structure of HLA-C08 in complex with a tumor mut10m peptide | | 分子名称: | 10-mer peptide, Beta-2-microglobulin, HLA class I antigen, ... | | 著者 | Bai, P, Zhou, Q, Wei, P, Yin, L. | | 登録日 | 2019-04-11 | | 公開日 | 2020-04-15 | | 最終更新日 | 2021-02-17 | | 実験手法 | X-RAY DIFFRACTION (1.9 Å) | | 主引用文献 | Immune-based mutation classification enables neoantigen prioritization and immune feature discovery in cancer immunotherapy.
Oncoimmunology, 10, 2021
|
|
6JTP
 | | Crystal structure of HLA-C08 in complex with a tumor mut9m peptide | | 分子名称: | 9-mer peptide, Beta-2-microglobulin, HLA class I antigen, ... | | 著者 | Bai, P, Zhou, Q, Wei, P, Lei, Y. | | 登録日 | 2019-04-11 | | 公開日 | 2020-04-15 | | 最終更新日 | 2021-02-17 | | 実験手法 | X-RAY DIFFRACTION (1.9 Å) | | 主引用文献 | Immune-based mutation classification enables neoantigen prioritization and immune feature discovery in cancer immunotherapy.
Oncoimmunology, 10, 2021
|
|
6JQ2
 | | Crystal Structure of H2-Kb in complex with a DPAGT1 self-peptide | | 分子名称: | Beta-2-microglobulin, DPATG1 antigen SIIVFNLV, H-2 class I histocompatibility antigen, ... | | 著者 | Bai, P, Yin, L. | | 登録日 | 2019-03-28 | | 公開日 | 2020-04-01 | | 最終更新日 | 2021-02-17 | | 実験手法 | X-RAY DIFFRACTION (2.4 Å) | | 主引用文献 | Immune-based mutation classification enables neoantigen prioritization and immune feature discovery in cancer immunotherapy.
Oncoimmunology, 10, 2021
|
|
